Published in BMC Infect Dis on June 09, 2011
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol (2012) 0.96
Current and future directions for treating hepatitis B virus infection. World J Hepatol (2015) 0.85
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. J Res Med Sci (2012) 0.82
Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion. World J Gastroenterol (2015) 0.77
CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study. Medicine (Baltimore) (2016) 0.75
Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report. J Venom Anim Toxins Incl Trop Dis (2013) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Chronic hepatitis B. Hepatology (2007) 13.75
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol (2008) 9.14
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Hepatitis B virus infection. Lancet (2009) 5.78
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Chronic hepatitis B: update of recommendations. Hepatology (2004) 2.69
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol (2002) 2.57
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 2.29
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med (2005) 1.97
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology (2008) 1.56
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology (2009) 1.48
Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology (2010) 1.43
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol (2008) 1.36
Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol (2008) 1.32
Hepatitis B: diagnosis and treatment. Am Fam Physician (2010) 0.95
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther (2009) 0.94
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology (2005) 0.88
Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother (2007) 0.83
[A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi (2010) 0.78
HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver Int (2009) 0.77
[Pegylated interferon alpha 2a in treating chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi (2006) 0.77
Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol (2010) 0.98
Fuzheng Huayu recipe prevents nutritional fibrosing steatohepatitis in mice. Lipids Health Dis (2012) 0.86
Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis (2013) 0.86
Genetic characteristics and pathogenicity of human hepatitis E virus in Nanjing, China. World J Gastroenterol (2012) 0.85
Atrial autonomic innervation remodelling and atrial fibrillation inducibility after epicardial ganglionic plexi ablation. Europace (2010) 0.79
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C]. Zhonghua Gan Zang Bing Za Zhi (2013) 0.77
A Patient With Primary Biliary Cirrhosis Accompanied by Wilson's Disease. Hepat Mon (2016) 0.75
[The significance of resistin expression in livers of patients with nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi (2008) 0.75
[Antiviral therapy of HCV infection in patients with uraemia on maintenance of hemodialysis and waiting for renal transplantation: a case report]. Zhonghua Gan Zang Bing Za Zhi (2011) 0.75
[Molecular identification in genus of Lilium based on DNA barcoding]. Yao Xue Xue Bao (2014) 0.75
[Research advances on hepatitis B virus covalently closed circular DNA]. Zhonghua Gan Zang Bing Za Zhi (2011) 0.75